Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
Status:
Completed
Trial end date:
2016-12-20
Target enrollment:
Participant gender:
Summary
Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory
reaction involving ocular tissue and vasculature. The inflammation usually causes pain,
redness, photophobia and blurred vision. This inflammation, is typically treated with
regional or systemic therapy. The regional therapy typically consists of topical
corticosteroids or periocular or regional corticosteroids. Regional therapy can lead to a
steroid response glaucoma, which is increased intraocular pressure.This pilot study aims to
evaluate the possible effectiveness of H.P. Acthar in patients with active ocular
inflammatory disease, and currently on treatment for glaucoma or have a history of glaucoma.